Castle Biosciences (CSTL) Q1 2026: Tissue Cipher Volume Up 58%, Propelling Guidance Hike

2026-05-06 | By EarningsIQ Research

Tissue Cipher, molecular risk test, delivered standout 58% volume growth, driving Castle Biosciences to raise 2026 revenue guidance. Core franchises are scaling, but seasonality and expense growth signal a more complex margin path ahead. Management’s disciplined expansion and early ADTX, atopic dermatitis test, traction set the stage for multi-year growth, though reimbursement and cash flow remain key watchpoints.

Summary

• Tissue Cipher Emerges as Growth Engine: Gastroenterology test volumes surged, outpacing legacy melanoma growth rates.
• Margin Leverage Faces Expense Headwinds: Higher personnel, lab, and R&D costs are offsetting top-line gains.
• ADTX and M&A Optionality Shape Future: Early ADTX uptake and active M&A screening position CSTL for portfolio expansion.

Business Overview

Castle Biosciences develops and commercializes molecular diagnostic tests that guide treatment decisions for dermatologic cancers and gastrointestinal diseases. The company’s revenue model is based on test volume and reimbursement, with major segments including DecisionDx Melanoma, a gene expression profile test for skin cancer risk, and Tissue Cipher, a molecular test for Barrett’s esophagus risk stratification. Newer offerings like Advanced ADTX, for atopic dermatitis therapy selection, are in early commercialization stages.

Performance Analysis

Revenue rose on the strength of core franchises, with total sales reaching $83.7 million, supported by a 36% increase in overall test report volumes. The standout was Tissue Cipher, which posted 58% year-over-year growth in test report volumes, reflecting accelerating adoption among gastroenterologists. DecisionDx Melanoma—the company’s foundational dermatology test—delivered 16% volume growth, with March setting an all-time record.

Gross margin rebounded to 72.8% after a prior-year one-time amortization drag, but adjusted gross margin slipped to 75.6%, reflecting higher cost of sales from expanded lab operations and headcount. Operating expenses increased, notably in sales and marketing (up $4.2 million) and R&D (up $1.8 million), as Castle scaled its commercial and clinical footprint. Net loss narrowed to $14.5 million, but cash used in operations and investing was significant, reflecting bonus payments and ongoing investment in growth infrastructure.

• Tissue Cipher Outpaces Melanoma: GI franchise now rivals legacy dermatology in growth contribution and is driving guidance upside.
• Expense Growth Tracks Volume: Higher personnel and lab costs are necessary to support test adoption but pressure margin structure.
• Cash Burn Remains Material: Operating and investing cash outflows highlight the importance of discipline as growth investments continue.

Castle’s growth is real and diversified, but the cost structure will require careful management as newer tests scale and reimbursement lags persist.

Executive Commentary

Strategic Positioning

1. Tissue Cipher as New Growth Anchor

Tissue Cipher’s rapid adoption in gastroenterology is now the primary driver of upside, with management expecting to add a similar number of tests in 2026 as in 2025, pointing to nearly 50% annual growth. Clinical studies presented at major conferences are reinforcing its utility in real-world patient management, deepening its clinical moat.

2. DecisionDx Melanoma: Durable but Maturing

Melanoma remains a resilient franchise, but management now expects mid to high single-digit volume growth for the year, reflecting maturation and tougher comps. New clinical data continue to validate its risk stratification, but guideline politics and market penetration are tempering incremental acceleration.

3. ADTX: Early Traction, Long Reimbursement Cycle

Advanced ADTX’s limited-access launch saw 650 orders in Q1, signaling strong clinician interest. However, management cautions that meaningful reimbursement clarity will not come until late Q3, and material revenue contribution is unlikely before 2027, with potential for pharma partnerships providing optionality.

4. Commercial and Lab Expansion

Salesforce and lab headcount are expanding in anticipation of sustained volume growth, with fewer than 100 reps covering both dermatology and GI. A new Phoenix lab is coming online to stay ahead of capacity needs, though management sees minimal gross margin impact from the move.

5. M&A as a Growth Lever

With $261.7 million in cash and equivalents, Castle is actively screening for M&A targets that fit its strategic criteria but is exercising discipline, emphasizing only “Goldilocks” opportunities will be pursued to complement organic growth.

Key Considerations

This quarter underscores a business in transition from single-product dependency to a multi-franchise model, with operational scale up and pipeline bets shaping future returns. Investors must weigh accelerating test adoption against expense discipline and reimbursement risk.

Key Considerations:

• GI Franchise Momentum: Tissue Cipher’s outperformance is now central to the growth narrative and guidance upgrades.
• Expense Leverage Watch: Margin compression from higher personnel and lab costs could persist as volume scales and new tests ramp.
• ADTX Revenue Timing: Reimbursement clarity remains a gating factor for material revenue, with management targeting late 2026 for updates.
• M&A Discipline: Ample cash provides optionality, but management is signaling a measured approach to acquisitions.
• Seasonality Emerges: First signs of volume seasonality in GI point to a maturing franchise and more predictable quarterly trends.

Risks

Reimbursement delays for new tests, particularly ADTX, could push out revenue realization and pressure cash flow. Margin pressure from rising operating expenses may persist if volume growth slows or pricing erodes. Clinical guideline shifts, especially for melanoma, expose the business to non-market forces that could affect adoption rates. Finally, M&A execution risk looms if inorganic bets do not deliver expected synergies or growth.

Forward Outlook

For Q2 2026, Castle expects continued strong volume growth in both core and emerging franchises, with particular focus on sustaining Tissue Cipher momentum.

• Q2 test volumes projected to rise sequentially, with seasonality moderating GI growth in Q1 but ramping through the year.
• Gross margin expected to remain stable, pending lab transition and ongoing investment in sales and R&D.

For full-year 2026, management raised revenue guidance to $345 million to $355 million, reflecting confidence in core test adoption and pipeline progress.

• Full-year test volume growth led by Tissue Cipher, with DecisionDx Melanoma guiding for mid to high single-digit growth.
• ADTX reimbursement clarity targeted for late Q3, with broader rollout and revenue ramp expected in 2027–2028.

Management emphasized clinical evidence generation, disciplined expense management, and M&A optionality as key levers for value creation in the coming quarters.

• Seasonality now a factor in GI volumes, with Q1 typically lower than subsequent quarters.
• Lab and field force expansion to stay ahead of anticipated demand.

Takeaways

Castle Biosciences is demonstrating the power of a diversified molecular diagnostics portfolio, with Tissue Cipher now rivaling melanoma as a core growth engine. Margin discipline and reimbursement progress will determine the pace of operating leverage and cash flow improvement.

• GI Test Outperformance: Tissue Cipher’s rapid adoption is driving guidance upgrades and positioning Castle as a multi-vertical diagnostics leader.
• Margin and Cash Flow in Focus: Expense growth is tracking with volume, but investors should monitor for signs of operating leverage as newer tests scale and reimbursement matures.
• ADTX and M&A Optionality: Early ADTX traction and a strong cash position create optionality, but execution on reimbursement and disciplined dealmaking are critical for long-term value.

Conclusion

Castle Biosciences delivered a breakout quarter for its GI franchise, raising guidance and cementing its transition to a multi-product growth model. The company’s ability to manage expense growth and deliver on reimbursement for new tests will shape its path to profitability and sustained leadership in molecular diagnostics.

Industry Read-Through

Castle’s results highlight a broader shift in diagnostics toward multi-vertical portfolios, with GI and dermatology franchises both contributing meaningfully to growth. Seasonality and reimbursement cycles are becoming more pronounced as test adoption matures, underscoring the need for operational agility and robust clinical evidence. Competitors in molecular diagnostics should note the importance of diversified test menus, proactive capacity planning, and evidence-driven market access strategies. Margin management and capital allocation discipline will remain key differentiators as the sector scales and payor scrutiny intensifies.

CSTL Healthcare Diagnostics Molecular Testing Dermatology Gastroenterology Reimbursement Growth